Rhythm Pharmaceuticals Announces Proposed Public Offering of $150 Million in Common Stock

Strategic Insights -

Rhythm Pharmaceuticals, a global commercial-stage biopharmaceutical company, has announced a proposed public offering of $150 million in common stock, with an option to purchase an additional $22.5 million in shares. The offering is being led by Morgan Stanley, BofA Securities, Stifel, and Wells Fargo Securities, and is subject to market and customary closing conditions. The company expects to file a final prospectus supplement with the Securities and Exchange Commission (SEC) and will make the offering available through various means, including the company's website and the SEC's website.

Key Takeaways:

  • The proposed public offering is for $150 million in common stock, with an option to purchase an additional $22.5 million in shares.
  • The offering is being led by Morgan Stanley, BofA Securities, Stifel, and Wells Fargo Securities.
  • The company filed a shelf registration statement on Form S-3 with the SEC on March 2, 2023, which automatically became effective.
  • The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.
  • Rhythm Pharmaceuticals is a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases.

Statistics:

  • $150 million: The proposed amount of the public offering.
  • $22.5 million: The amount available for purchase by the underwriters through an option to purchase additional shares.
  • 30 days: The option period granted to the underwriters to purchase additional shares.
  • 2023: The year in which the shelf registration statement on Form S-3 was filed with the SEC.
  • 2024: The year in which Rhythm Pharmaceuticals' Annual Report on Form 10-K was filed with the SEC.
  • July 09, 2023: The date on which the company announced the proposed public offering.

Sources:

  • Globe Newswire, "Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of $150 Million of Common Stock", July 09, 2025.
  • Securities and Exchange Commission, Rhythm Pharmaceuticals, Inc. Form 10-K for the year ended December 31, 2024.
  • Securities and Exchange Commission, Rhythm Pharmaceuticals, Inc. Form S-3 registration statement filed on March 2, 2023.